Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.97)
# 1,372
Out of 5,126 analysts
53
Total ratings
30%
Success rate
6.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $17.10 | +332.75% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $6.67 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $68.10 | +29.22% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $14.99 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $47.62 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $72.90 | +31.69% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.91 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.63 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $26.19 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $15.36 | -15.30% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.01 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $48.74 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $108.39 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $26.53 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.51 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.98 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $201.18 | +45.14% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $477.92 | -22.58% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.82 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.60 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $17.10
Upside: +332.75%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $6.67
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $68.10
Upside: +29.22%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $14.99
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $47.62
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $72.90
Upside: +31.69%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.91
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.63
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $26.19
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $15.36
Upside: -15.30%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.01
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $48.74
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $108.39
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $26.53
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.51
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.98
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $201.18
Upside: +45.14%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $477.92
Upside: -22.58%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $1.82
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.60
Upside: -